Navigation Links
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
Date:4/27/2011

ct candidates and research and clinical programs now underway or planned, the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that may be superior to Regeneron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with the sanofi-aventis Group and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property and pending or future litigation relating thereto.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2010.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise, unless required by law.

Bayer Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management.  Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.  These factors include those discussed in Bayer's public reports which are available on the Bayer website at '/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
2. Regeneron Announces Presentation at the 10th Annual Needham Healthcare Conference
3. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
4. Regeneron Announces March 2011 Investor Conference Presentations
5. Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
6. Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
7. Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET
8. Regeneron Announces Presentation at the ISI Annual Conference
9. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
10. Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
11. Christine A. Poon Elected to Regeneron Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 1, 2014 In the latest call for ... dysfunction, more than 60 doctors and leading medical experts ... questioning the Food and Drug Administration,s (FDA) decision to ... of male sexual dysfunction compared with ZERO for women,s ... act for women by approving the first-ever drug to ...
(Date:8/1/2014)... 2014 In the latest call for gender ... more than 60 doctors and leading medical experts from ... the Food and Drug Administration,s (FDA) decision to approve ... male sexual dysfunction compared with ZERO for women,s most ... for women by approving the first-ever drug to treat ...
(Date:8/1/2014)... Aspire Technology Partners (Aspire) announced today that it ... This designation recognizes Aspire for delivering outstanding customer service to ... . "Achieving exceptional results for our customers is ... President and CEO of Aspire. "We are pleased Cisco has ... award and are proud to be part of the Cisco ...
Breaking Medicine Technology:60+ Healthcare Professionals Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Healthcare Professionals Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 360+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 3Aspire Technology Partners Recognized By Cisco For Excellence In Customer Satisfaction 2
... May 3, 2012 /PRNewswire-Asia/ -- Johnson & ... has acquired Guangzhou Bioseal Biotechnology Co., Ltd. ... in the design, development and commercialization of ... bleeding during surgery. The acquisition was completed ...
... Cochlear Americas , the world,s leading implantable hearing ... smartphone support application for Nucleus® Cochlear Implant recipients. ... App as part of Cochlear,s mobile support initiative, ... and wherever they need it. (Photo: ...
Cached Medicine Technology:Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd. 2Cochlear™ Americas Adds the Nucleus® Support App to its Mobile Service Offerings 2
(Date:8/1/2014)... Medicine in St. Louis helps explain why brain tumors ... harmful than similar tumors in females. For example, glioblastomas, ... as often in males, who suffer greater cognitive impairments ... The researchers found that retinoblastoma protein (RB), a protein ... in male brain cells than in female brain cells. ...
(Date:8/1/2014)... News) -- The U.S. Food and Drug Administration announced ... to help fight type 2 diabetes. Jardiance ... treatment regimens to control blood sugar levels in the ... the Office of Drug Evaluation II in the FDA,s ... agency statement. The FDA also recommended that Jardiance ...
(Date:8/1/2014)... August 01, 2014 The evolving ... independent community pharmacies. At ThoughtSpot 2014, AmerisourceBergen and ... with practices and resources to enhance patient care ... focused on critical issues to give independent pharmacists ... grow. , ThoughtSpot show attendance experienced a ...
(Date:8/1/2014)... Texas (PRWEB) August 01, 2014 ... health coverage and healthcare reforms are boosting healthcare ... of medicines through discounts and increasing generic consumption ... at approximately 76.7 million in 2013, having grown ... 1.4%, from 2008. The implementation of the Health ...
(Date:8/1/2014)... News) -- Patients with the progressive, deadly respiratory ailment ... new weapon to battle the disease, the U.S. Food ... approved a new treatment, an inhaled spray called Striverdi ... Americans. COPD, which is often linked to smoking, involves ... Patients with COPD may experience a number ...
Breaking Medicine News(10 mins):Health News:Study reveals one reason brain tumors are more common in men 2Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:FDA Approves New Treatment for People With COPD 2
... industrial chemicals in the environment can damage the developing ... deficit disorder (ADHD), and mental retardation. Still, there has ... that can cause injury to the developing brains of ... in the print issue of The Lancet researchers from ...
... 47-year-old woman who lost her hands in a chemical explosion some ... This is the first of its kind done in Spain, and ... the Pedro Cavadas Foundation performed this ten- hour operation. ... and may be released from hospital next week and should get ...
... US HIV/AIDS healthcare provider will soon be reaching out ... Assam to provide treatment and support//. ,The US-based ... counselling and testing centres in Assam's main city of ... city of Silchar. ,India's National AIDS ...
... with yet another significant product from soybean. A study ... made from soy has amazing restorative powers. ... Jefferson Medical College found that giving doses of a ... animals’ ability to move and walk. ,Over ...
... the senior citizens have become sensitive to health issues, and ... under control. ,Study author, Bernard M.Y. Cheung, said,"It ... We have tried to see if the explanation lies in ... increase in these, so probably all of these contribute in ...
... now be made more easily available to critically ill patients. ... that will enable patients// who are extremely ill to try ... options. ,The FDA has announced that they will ... to be made available to needy individuals .They will also ...
Cached Medicine News:Health News:Industrial Chemicals Are Impairing the Brain Development of Children Worldwide 2Health News:Industrial Chemicals Are Impairing the Brain Development of Children Worldwide 3Health News:Industrial Chemicals Are Impairing the Brain Development of Children Worldwide 4Health News:US NGO to Counsel HIV/AIDS Patients in Assam 2Health News:Soy’s Restorative Powers Confirme 2
The Hilan pneumatic high speed drill system consists of a pneumatic motor and drill with various cutting attachments....
The XK-95 High Speed Drill System sets new technological and performance standards for surgical drill systems....
Circular Spine Retractor System for microsurgical interventions in the lumbar and cervical spine region. The system has been approved in over 120 cases....
... The Ruggles Retractor System, a ... and the versatility of two systems ... hands from the surgical site during ... accurate retractor insertion. The retractor body ...
Medicine Products: